Document Detail

Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease.
MedLine Citation:
PMID:  9007136     Owner:  NLM     Status:  MEDLINE    
Based on superior results observed with combined-modality therapy over radiotherapy alone and on the authors' previous work with carboplatin and standard daily thoracic radiotherapy in patients with advanced, unresectable non-small cell lung cancer, a phase II study was designed to incorporate radiosensitizing doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) into the carboplatin/radiotherapy regimen, to improve the therapeutic index and define the toxicities. Thirty-two patients have been entered. Paclitaxel 45 mg/m2/wk was administered over 3 hours prior to carboplatin (100 mg/m2/wk) and thoracic radiotherapy (1.8 Gy/d 5 days a week; total dose, 60 to 65 Gy). No grade 4 toxicities occurred. Seven patients had chemotherapy doses delayed because of grade 3 neutropenia, and one patient had grade 3 mucositis/esophagitis that required hospitalization. Median survival has not yet been reached, and all patients are being followed. These preliminary data demonstrate the feasibility of combined concurrent chemoradiotherapy, with acceptable toxicities. Further investigation is needed to optimize carboplatin dosage with adaptive control using formulas based on pharmacokinetics and pharmacodynamics. Full-dose induction chemotherapy regimens to maximize the systemic effects of chemotherapy should precede concurrent chemoradiotherapy in future studies.
C P Belani; J Aisner; S Bahri; J Jett; R Day; M J Capazolli; D Hiponia; C Engstrom
Related Documents :
8355046 - Phase i clinical trial of carboplatin and 41.8 degrees c whole-body hyperthermia in can...
19337916 - Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and h...
9007126 - Paclitaxel and carboplatin in inoperable non-small cell lung cancer.
21477946 - Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dime...
20425396 - Challenges in the frontline treatment of patients with chronic lymphocytic leukemia.
10761786 - Long-term results of a multi-institutional randomized trial comparing prognostic factor...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Seminars in oncology     Volume:  23     ISSN:  0093-7754     ISO Abbreviation:  Semin. Oncol.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-02-25     Completed Date:  1997-02-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0420432     Medline TA:  Semin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  113-6     Citation Subset:  IM    
Department of Medicine, University of Pittsburgh School of Medicine and the University of Pittsburgh Cancer Institute, PA 15213, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / administration & dosage*,  toxicity
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  toxicity
Carboplatin / administration & dosage
Carcinoma, Non-Small-Cell Lung / radiotherapy,  therapy*
Combined Modality Therapy
Drug Administration Schedule
Esophagitis / chemically induced
Lung Neoplasms / radiotherapy,  therapy*
Middle Aged
Mucous Membrane / drug effects
Neutropenia / chemically induced
Paclitaxel / administration & dosage*,  toxicity
Radiation-Sensitizing Agents / administration & dosage*,  toxicity
Survival Rate
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Radiation-Sensitizing Agents; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Paclitaxel and simultaneous radiation in the treatment of stage IIIA/B non-small cell lung cancer.
Next Document:  Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-...